Safety Profile Overview
Anti-VEGF intravitreal injection for wet AMD, DME, and retinal vein occlusion. One of the highest-revenue ophthalmology drugs globally.
Generic Name
aflibercept
Brand Names
Eylea
Therapeutic Class
VEGF Trap
Manufacturer
Regeneron
What Pharma Signal Tracks for Eylea
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Eylea, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Eylea products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Eylea Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Eylea.
curl "https://api.pharma-signal.com/drug/safety/eylea" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Eylea against other VEGF Trap drugs, or explore the full manufacturer portfolio for Regeneron.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Eylea ranks within VEGF Trap on serious event rates.
- Company portfolio risk — View all drugs from Regeneron with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.